Abstract

The effect of preoperative immunonutrition intake on postoperative major complications in patients following cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) was assessed. The accuracy of C-Reactive Protein (CRP) for detecting postoperative complications was also analyzed. Patients treated within a peritoneal carcinomatosis program in which a complete or optimal cytoreduction was achieved were retrospectively analyzed. They were divided into two groups based on whether preoperative immunonutrition (IMN) or not (non-IMN) were administered. Clinical and surgical variables and postoperative complications were gathered. Predictive values of major morbidity of CRP during the first 3 postoperative days (POD) were also evaluated. A total of 107 patients were included, 48 belonging to the IMN group and 59 to the non-IMN group. In multivariate analysis immunonutrition (OR 0.247; 95%CI 0.071–0.859; p = 0.028), and the number of visceral resections (OR 1.947; 95%CI 1.086–3.488; p = 0.025) emerged as independent factors associated with postoperative major morbidity. CRP values above 103 mg/L yielded a negative predictive value of 84%. Preoperative intake of immunonutrition was associated with a decrease of postoperative major morbidity and might be recommended to patients with peritoneal carcinomatosis following CRS. Measuring CRP levels during the 3 first postoperative days is useful to rule out major morbidity.

Highlights

  • Until 20 years ago, peritoneal carcinomatosis from gastrointestinal cancers was considered a terminal stage and these patients received only palliative treatment

  • All patients treated for peritoneal carcinomatosis within a peritoneal carcinomatosis program at the Elche University General Hospital from November 2014 to November 2020 were initially considered

  • Only those patients in whom a complete or optimal cytoreduction was achieved after cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) were included in the study

Read more

Summary

Introduction

Until 20 years ago, peritoneal carcinomatosis from gastrointestinal cancers was considered a terminal stage and these patients received only palliative treatment. The development of cytoreductive surgery (CRS) alone or in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) has been increasingly introduced to treat peritoneal metastasis of some neoplasms with curative intent [1,2]. Nowadays, it is considered the standard of care to treat peritoneal pseudomyxoma and mesothelioma while CRS alone or in combination with HIPEC has been shown to improve overall and disease-free survival in peritoneal carcinomatosis of ovarian and colonic origin [3,4,5]. Postoperative major morbidity constitutes a life-threatening side effect but may jeopardize long-term survival and quality of life [13,14]

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call